ONCAlert | 2017 San Antonio Breast Cancer Symposium

The Future of XMT-1536 in Ovarian Cancer and NSCLC

Don Bergstrom
Published Online:9:51 AM, Wed September 14, 2016

Don Bergstrom, MD, PhD, chief medical officer, Mersana Therapeutics, discusses the future of XMT-1536 in the treatment of ovarian cancer and non-small cell lung cancer (NSCLC).
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.